Stay updated on Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page
- Check2 days agoChange DetectedThe page revision history was updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded a Locations section with Virginia and its details; removed the HHS Vulnerability Disclosure and Virginia Locations, and updated to Revision: v3.3.3.SummaryDifference0.2%

- Check31 days agoChange DetectedThe page now shows 'Results Submitted' instead of 'No Results Posted', indicating that trial results have been submitted.SummaryDifference0.1%

- Check53 days agoChange DetectedFooter revision tag updated from v3.2.0 to v3.3.2 with no changes to study details or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedA government funding status notice previously shown on the page has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check74 days agoChange DetectedStudy Completion (Estimated) is now listed as 2031-01, and the Study Record Dates show a new update (Last Update Posted 2025-03-27) with QC criteria updates.SummaryDifference0.5%

Stay in the know with updates to Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.